Thanks Thanks:  0
Recommend Recommend:  0
Likes Likes:  0
  1. #1
    Presser's Avatar
    Join Date
    May 2002
    Posts
    41,688
    Rep Power
    2147525357

    Default Use of recombinant IGF-I lowers fasting insulin and abdominal fat in patients

    In vitro and in vivo effects of IGF-I on adiposity in HIV-associated metabolic disease: a pilot study.

    Kim RJ1, Vaghani S, Zifchak LM, Quinn JH, He W, Tebas P, Frank I.
    Author information


    Abstract

    BACKGROUND AND AIMS:

    We tested the effects of recombinant insulin-like growth factor-I (IGF-I) in an adipocyte model of HIV lipodystrophy and in an open label study on body composition and metabolism in patients with HIV lipodystrophy.
    METHODS:

    The effects of IGF-I on ritonavir-induced adipocyte cell death were studied in vitro. We assessed lipid accumulation, IGF signaling, apoptosis, and gene expression. We conducted a 24-week open label trial of recombinant IGF-I in ten adults with HIV associated lipoatrophy. Laboratory assessments included glucose, insulin, lipids, and IGF-I. At weeks 0 and 24, body composition studies were performed including skinfold measurement, dual-energy x-ray absorptiometry, and computed tomography of the abdomen and thigh.
    RESULTS:

    In vitro, ritonavir increased delipidation and apoptosis of adipocytes, whereas co-treatment with IGF-I attenuated the effect. In the clinical study, subcutaneous adipose tissue did not increase in patients after treatment with IGF-I; however, there was a decrease in the proportion of abdominal fat (39.8 ± 7% vs. 34.6 ± 7%, p = 0.007). IGF-I levels increased with treatment (143 ± 28 μg/L at week 0 vs. 453 ± 212 μg/L at week 24, p = 0.002), whereas IGFBP-3 levels declined (3.554 ± 1.146 mg/L vs. 3.235 ± 1.151 mg/L, p = 0.02). Insulin at week 12 decreased significantly (90.1 ± 39.8 pmol/L vs. 33.2 ± 19.6 pmol/L, p = 0.002). There was a nonsignificant decrease in visceral adipose tissue (155.2 ± 68 cm² at week 0 vs. 140.6 ± 70 cm² at week 24, p = 0.08).
    CONCLUSIONS:

    Use of recombinant IGF-I may lower fasting insulin and abdominal fat in patients with lipoatrophy associated with HIV infection. Further evaluation of this agent for treatment of HIV-associated lipodystrophy may be warranted.

    Use of recombinant IGF-I  lowers fasting insulin and abdominal fat in patients

  2. #2
    Presser's Avatar
    Join Date
    May 2002
    Posts
    41,688
    Rep Power
    2147525357

    Default

    Effects of insulin-like growth factor (IGF)-I/IGF-binding protein-3 treatment on glucose metabolism and fat distribution in human immunodeficiency virus-infected patients with abdominal obesity and insulin resistance.

    Rao MN1, Mulligan K, Tai V, Wen MJ, Dyachenko A, Weinberg M, Li X, Lang T, Grunfeld C, Schwarz JM, Schambelan M.
    Author information


    Abstract

    CONTEXT:

    HIV-infected patients on antiretroviral therapy are at increased risk for excess visceral adiposity and insulin resistance. Treatment with GH decreases visceral adiposity but worsens glucose metabolism. IGF-I, which mediates many of the effects of GH, improves insulin sensitivity in HIV-negative individuals.
    OBJECTIVE:

    Our objective was to determine whether IGF-I, complexed to its major binding protein, IGF-binding protein-3 (IGFBP-3), improves glucose metabolism and alters body fat distribution in HIV-infected patients with abdominal obesity and insulin resistance.
    METHODS:

    We conducted a pilot, open-label study in 13 HIV-infected men with excess abdominal adiposity and insulin resistance to assess the effect of 3 months of treatment with IGF-I/IGFBP-3 on glucose metabolism and fat distribution. Glucose metabolism was assessed by oral glucose tolerance test and hyperinsulinemic-euglycemic clamp. Endogenous glucose production (EGP), gluconeogenesis, whole-body lipolysis, and de novo lipogenesis (DNL) were measured with stable isotope infusions. Body composition was assessed by dual-energy x-ray absorptiometry and abdominal computed tomography scan.
    RESULTS:

    Glucose tolerance improved and insulin-mediated glucose uptake increased significantly during treatment. EGP increased under fasting conditions, and suppression of EGP by insulin was blunted. Fasting triglycerides decreased significantly in association with a decrease in hepatic DNL. Lean body mass increased and total body fat decreased, whereas visceral adipose tissue did not change.
    CONCLUSIONS:

    Treatment with IGF-I/IGFBP-3 improved whole-body glucose uptake and glucose tolerance, while increasing hepatic glucose production. Fasting triglycerides improved, reflecting decreased DNL, and visceral adiposity was unchanged.

    Use of recombinant IGF-I  lowers fasting insulin and abdominal fat in patients

Similar Threads

  1. Replies: 0
    Last Post: 03-26-2016, 08:31 AM
  2. Replies: 4
    Last Post: 02-01-2016, 04:44 PM
  3. Intermittent Fasting For Fat Loss and Muscle Gains. Carb Cycle , Insulin Manipulation
    By Presser in forum Bodybuilding Steroid & Training Articles
    Replies: 1
    Last Post: 04-20-2014, 09:03 AM
  4. Insulin-Like Growth Factor Recombinant 3
    By Bently in forum Peptide HGH IGF 1 Discussion
    Replies: 4
    Last Post: 03-25-2014, 10:01 AM
  5. HGH vs recombinant HGH
    By Hurilla in forum Peptide HGH IGF 1 Discussion
    Replies: 7
    Last Post: 04-14-2005, 09:23 PM

Tags for this Thread

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •  

Log in

Log in